Abcam, ab258403, Human ECE2 knockout HeLa cell lysate

Size: 1Kit
EEF1AKMT4-ECE2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 8 bp deletion in exon 1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 8 bp deletion in exon 1,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-EEF1AKMT4-ECE2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ECE2 also known as Endothelin-Converting Enzyme 2 is a metalloprotease with a molecular mass of approximately 85 kDa. It plays a role in converting inactive big endothelins into active endothelins which are potent vasoactive peptides. You find ECE2 expressed in various tissues including the brain heart and lungs. The protein localizes mainly to the cell membrane and endosomal compartments where it performs its enzymatic functions.
Biological function summary
ECE2 has a significant role in the regulation of vascular tone and blood pressure. It is an integral part of the endothelin system not forming a complex but working along with endothelin receptors to modulate vasoconstriction and vasodilation. Its activity helps maintain cardiovascular homeostasis. The enzyme processes peptides that influence neuronal signaling suggesting a role in neural function as well.
Pathways
ECE2 features prominently in the endothelin signaling pathway and the broader cardiovascular regulatory pathway. It processes the precursor proteins big endothelins which then activate endothelin receptors (EDNRA EDNRB). These receptors further engage with G-proteins to promote downstream signaling that regulates vascular constriction and blood pressure. ECE2 activity is important for ensuring the balance of these signaling cascades particularly in cardiovascular and neural contexts.
ECE2 plays a part in the pathophysiology of hypertension and Alzheimer's disease. Altered ECE2 activity influences endothelin levels contributing to blood pressure dysregulation and hypertension. In Alzheimer's disease ECE2 works with proteins like beta-amyloid peptide where dysregulation may lead to neurotoxicity and plaque formation. These connections make ECE2 a potential therapeutic target in disease intervention.